OpenAI acquires Orchestra Bio to expand Rosalind for drug R&D
According to OpenAI and Greg Brockman on X, OpenAI has acquired Orchestra Bio to integrate its coordination platform with Rosalind AI tools, aiming to streamline biopharma drug development operations and speed treatments to patients.
SourceAnalysis
OpenAI acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development, as announced by Greg Brockman on October 21, 2026.
The move builds on Rosalind, OpenAI's AI models and tools for life sciences research, to streamline operations and accelerate new treatments reaching patients, representing an emerging application of the models toward drug development acceleration, according to the announcement from OpenAI.
Greg Brockman
@gdbPresident & Co-Founder of OpenAI